U.S. CPI looms large; Oracle, Adobe report – what’s moving markets

U.S. CPI looms large; Oracle, Adobe report – what’s moving markets

U.S. CPI looms large; Oracle, Adobe report – what’s moving markets
Wealthtech platform Orion has added BlackRock, Fidelity Investments and Vanguard models to its Tailored Allocation Portfolios program. The program, launched in the fall of 2025, pairs third-party models with Orion’s custom indexing technology to provide tax management and personalization at scale. It runs each asset manager’s ETF and mutual fund models through the technology, including…
A petite Cape Cod residence offering less than 800 square feet of living space has just hit the market in Provincetown, MA, for the sky-high asking price of $1.5 million. The asking price for the 788-square-foot residence translates to an astronomical $1,897 per square foot. But while that price tag might seem extraordinary, it is…
HM Land Registry has collaborated with Ordnance Survey to enhance data accessibility and innovation in the housing and geospatial sectors, aiming to “transform” the property market. The organisations said the move would reduce friction for people and businesses, while improving confidence in property rights and the wider housing sector. The two organisations have signed…
Mortgage rates are based on bonds, but whereas bonds improved slightly from Friday’s levels, mortgage rates are microscopically higher for the average lender. The issue is timing. Mortgage lenders set rates last Friday during a time of day when bonds were at their best levels. In other words, today’s improvement is only an improvement relative…
Systematic Investment Plans (SIPs) are one of the most popular ways for retail investors to invest in mutual funds. However, an expert suggests that starting a SIP alone does not guarantee a well-balanced mutual fund portfolio. According to Aditya Agarwal, Co-Founder, Wealthy.in, investors should treat SIPs as an investment execution tool rather than a complete…
LUND, Sweden, Aug. 18, 2026 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). “This first commercial living donor transplant patient in Australia…